Insulet Corporation (NASDAQ:PODD) Receives Consensus Rating of “Moderate Buy” from Brokerages

Insulet Corporation (NASDAQ:PODD) has been given a consensus rating of “Moderate Buy” by the twenty-eight ratings firms that are covering the firm, MarketBeat.com reports. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating and twenty-two have given a buy rating to the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $235.25.

PODD has been the subject of a number of analyst reports. Stifel Nicolaus lowered their target price on shares of Insulet from $250.00 to $225.00 and set a “buy” rating for the company in a research note on Friday, July 10th. Wells Fargo & Company cut their price target on shares of Insulet from $360.00 to $255.00 and set an “overweight” rating on the stock in a research report on Wednesday, May 6th. Leerink Partners decreased their price target on Insulet from $360.00 to $247.00 in a report on Thursday, May 7th. Barclays lowered their price objective on Insulet from $286.00 to $198.00 and set an “underweight” rating for the company in a research report on Thursday, May 7th. Finally, Truist Financial dropped their price objective on Insulet from $219.00 to $210.00 and set a “buy” rating on the stock in a research note on Monday.

Insiders Place Their Bets

In other Insulet news, Director Timothy C. Stonesifer bought 2,790 shares of the stock in a transaction on Wednesday, June 3rd. The stock was acquired at an average cost of $143.51 per share, for a total transaction of $400,392.90. Following the completion of the acquisition, the director owned 9,041 shares in the company, valued at $1,297,473.91. This trade represents a 44.63% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this link. Insiders own 0.36% of the company’s stock.

Hedge Funds Weigh In On Insulet

Institutional investors and hedge funds have recently modified their holdings of the business. Nordea Investment Management AB grew its holdings in Insulet by 35.0% in the fourth quarter. Nordea Investment Management AB now owns 551,133 shares of the medical instruments supplier’s stock worth $157,128,000 after purchasing an additional 142,922 shares during the period. Mitsubishi UFJ Trust & Banking Corp raised its holdings in shares of Insulet by 26.5% during the fourth quarter. Mitsubishi UFJ Trust & Banking Corp now owns 43,921 shares of the medical instruments supplier’s stock valued at $12,484,000 after purchasing an additional 9,206 shares during the period. Aberdeen Group plc raised its holdings in shares of Insulet by 45.6% during the fourth quarter. Aberdeen Group plc now owns 225,429 shares of the medical instruments supplier’s stock valued at $64,076,000 after purchasing an additional 70,607 shares during the period. Zevenbergen Capital Investments LLC bought a new position in shares of Insulet during the 4th quarter worth about $32,143,000. Finally, Gradient Investments LLC boosted its position in shares of Insulet by 17.9% during the 4th quarter. Gradient Investments LLC now owns 69,161 shares of the medical instruments supplier’s stock worth $19,658,000 after purchasing an additional 10,497 shares in the last quarter.

Insulet Stock Performance

NASDAQ:PODD opened at $164.43 on Friday. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.81 and a current ratio of 2.49. Insulet has a fifty-two week low of $138.79 and a fifty-two week high of $354.88. The company has a 50 day simple moving average of $152.81 and a two-hundred day simple moving average of $207.20. The company has a market capitalization of $11.39 billion, a PE ratio of 38.24, a P/E/G ratio of 1.11 and a beta of 1.11.

Insulet (NASDAQ:PODD) last issued its quarterly earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.19 by $0.23. Insulet had a net margin of 10.44% and a return on equity of 26.87%. The firm had revenue of $761.70 million for the quarter, compared to the consensus estimate of $729.89 million. During the same quarter in the previous year, the company earned $1.02 EPS. The company’s revenue for the quarter was up 33.9% on a year-over-year basis. Insulet has set its FY 2026 guidance at 6.210- EPS. Research analysts anticipate that Insulet will post 6.45 earnings per share for the current year.

Trending Headlines about Insulet

Here are the key news stories impacting Insulet this week:

• Neutral Sentiment: Multiple law firms issued reminders and investor alerts about a securities class action against Insulet, with lead-plaintiff deadlines set for August 31, 2026. These notices generally keep the stock in the spotlight but do not by themselves change the underlying case. Article link
• Neutral Sentiment: Another law firm announced that a class action lawsuit has been filed against Insulet and certain officers on behalf of investors who bought shares during the alleged class period, reinforcing concerns about legal overhang for the company. Article link
• Neutral Sentiment: Prior reporting cited allegations that two Omnipod corrections may have exposed broader quality-control issues and contributed to a sharp earlier selloff, which helps explain why litigation-related headlines remain a focus for traders. Article link

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.